The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer's disease continuum: A systematic review and meta-analysis with narrative synthesis

被引:17
作者
Yoong, Si Qi [1 ]
Lu, Jinhua [2 ,4 ]
Xing, Huimin [1 ]
Gyanwali, Bibek [3 ]
Tan, Yue Qian [1 ]
Wu, Xi Vivien [1 ,5 ]
机构
[1] Natl Univ Singapore, Yong Loo Lin Sch Med, Alice Lee Ctr Nursing Studies, Clin Res Ctr, Block MD11,Level 2,10 Med Dr, Singapore 117597, Singapore
[2] Natl Univ Singapore, Yong Yoo Lin Sch Med, Dept Microbiol & Immunol, Block MD4,Level 3,5 Sci Dr 2, Singapore 117545, Singapore
[3] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Block MD 7,8 Med Dr, Singapore 117596, Singapore
[4] Natl Univ Singapore, NUSMED Immunol Translat Res Programme, 28 Med Dr, Singapore 117456, Singapore
[5] Natl Univ Singapore, NUSMED Hlth Longev Translat Res Programme, 28 Med Dr, Singapore 117456, Singapore
关键词
CSF Neurogranin; Alzheimer's disease; Mild cognitive impairment; Cognitive decline; Biomarkers; CEREBROSPINAL-FLUID BIOMARKERS; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; AMYLOID-BETA; LEWY BODY; IMPAIRMENT; DEMENTIA; HYPOTHESIS; RECOMMENDATIONS;
D O I
10.1016/j.arr.2021.101491
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Core cerebrospinal fluid (CSF) biomarkers (A beta 42, T-tau, P-tau) were included as supporting diagnostic criteria for Alzheimer's Disease (AD), but they lack the power to predict AD progression. On the other hand, a new biomarker CSF Neurogranin (Ng) has been shown to predict cognitive decline. This systematic review aims to synthesise the prognostic utility of CSF Ng in predicting cognitive decline in the AD continuum. Seven databases were searched systematically from inception to 30 September 2020. Participants were 55 years or older, who had baseline and at least one follow-up cognitive assessments. Risk of bias was assessed using the Quality in Prognosis Studies tool. Meta-analysis was conducted by pooling standardised beta coefficients and adjusted hazard ratios. Thirteen studies were included and high-quality evidence suggests that CSF Ng predicts Mini-Mental State Examination (MMSE) decline in A beta+ mild cognitive impairment (MCI). Moderate quality evidence showed that CSF Ng could predict the decline of memory and executive function in MCI. Narrative synthesis found that CSF Ng/ A beta 42 was also likely to predict cognitive decline. More studies are required to validate the use of CSF Ng as an AD prognostic marker and its application in future development of drug treatment and diagnosis.
引用
收藏
页数:19
相关论文
共 113 条
  • [11] Frontotemporal dementia
    Bang, Jee
    Spina, Salvatore
    Miller, Bruce L.
    [J]. LANCET, 2015, 386 (10004) : 1672 - 1682
  • [12] Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank
    Barker, WW
    Luis, CA
    Kashuba, A
    Luis, M
    Harwood, DG
    Loewenstein, D
    Waters, C
    Jimison, P
    Shepherd, E
    Sevush, S
    Graff-Radford, N
    Newland, D
    Todd, M
    Miller, B
    Gold, M
    Heilman, K
    Doty, L
    Goodman, I
    Robinson, B
    Pearl, G
    Dickson, D
    Duara, R
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2002, 16 (04) : 203 - 212
  • [13] A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward
    Belloy, Michael E.
    Napolioni, Valerio
    Greicius, Michael D.
    [J]. NEURON, 2019, 101 (05) : 820 - 838
  • [14] Statistics review 12: Survival analysis
    Bewick, V
    Cheek, L
    Ball, J
    [J]. CRITICAL CARE, 2004, 8 (05): : 389 - 394
  • [15] Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays
    Blennow, Kaj
    Shaw, Leslie M.
    Stomrud, Erik
    Mattsson, Niklas
    Toledo, Jon B.
    Buck, Katharina
    Wahl, Simone
    Eichenlaub, Udo
    Lifke, Valeria
    Simon, Maryline
    Trojanowski, John Q.
    Hansson, Oskar
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [16] The Past and the Future of Alzheimer's Disease Fluid Biomarkers
    Blennow, Kaj
    Zetterberg, Henrik
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2018, 62 (03) : 1125 - 1140
  • [17] Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
    Blennow, Kaj
    Dubois, Bruno
    Fagan, Anne M.
    Lewczuk, Piotr
    de Leon, Mony J.
    Hampel, Harald
    [J]. ALZHEIMERS & DEMENTIA, 2015, 11 (01) : 58 - 69
  • [18] A basic introduction to fixed-effect and random-effects models for meta-analysis
    Borenstein, Michael
    Hedges, Larry V.
    Higgins, Julian P. T.
    Rothstein, Hannah R.
    [J]. RESEARCH SYNTHESIS METHODS, 2010, 1 (02) : 97 - 111
  • [19] Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum
    Bos, Isabelle
    Vos, Stephanie
    Verhey, Frans
    Scheltens, Philip
    Teunissen, Charlotte
    Engelborghs, Sebastiaan
    Sleegers, Kristel
    Frisoni, Giovanni
    Blin, Olivier
    Richardson, Jill C.
    Bordet, Regis
    Tsolaki, Magda
    Popp, Julius
    Peyratout, Gwendoline
    Martinez-Lage, Pablo
    Tainta, Mikel
    Lleo, Alberto
    Johannsen, Peter
    Freund-Levi, Yvonne
    Froelich, Lutz
    Vandenberghe, Rik
    Westwood, Sarah
    Dobricic, Valerija
    Barkhof, Frederik
    Legido-Quigley, Cristina
    Bertram, Lars
    Lovestone, Simon
    Streffer, Johannes
    Andreasson, Ulf
    Blennow, Kaj
    Zetterberg, Henrik
    Visser, Pieter Jelle
    [J]. ALZHEIMERS & DEMENTIA, 2019, 15 (05) : 644 - 654
  • [20] Budson A.E., 2017, MEMORY LOSS, ALZHEIMER's DISEASE AND DEMENTIA A Practical Guide for Clinicians, V2